Dr. Rimawi Discusses the Clinical Need for Immunotherapy in HER2-Positive Breast Cancer – OncLive
OncLive |
Dr. Rimawi Discusses the Clinical Need for Immunotherapy in HER2-Positive Breast Cancer
OncLive Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer … Can Immunotherapy in HER2+ Breast Cancer Suppress Trastuzumab Resistance? Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules … Pembrolizumab combination shows early potential for trastuzumab-resistant breast cancer |
